Protein Production
293FT, 293E, CHO

Truly Functional Protein
95% Purity
1-10 mg in 2 weeks

GeneExpressoMax™
293Expresso™

Transfection Reagents
* 90% Efficiency
* 95% Viability
* No sera interference
* Simple protocol
* High-throughput
* Only $98/ml

Baculovirus
Functional Protein
95% Purity
Fast turnaround
1-10 mg from Sf9 cells

Adenovirus, AAV
& Lentivirus

ORF or shRNA
* High Titer
* Cre, FLP, ΦC31
* Protein Kinases
* Transcription Factors
* Luciferases, GFP, RFP
* Protein Production
* Stable Cell Line


Excellgen

FIBRINOGEN-TRIGGERED MATRIX ASSEMBLY FROM DESIGNED PEPTIDE-POLYMER CONJUGATES

Andrew Louis
Georgia Institute Of Technologycity: Atlanta    country: United States (us)

Grant 1R21EB013743-01A1 from National Institute Of Biomedical Imaging And Bioengineering

Abstract: The need to control bleeding and bind damaged tissues represents a pressing and significant clinical need in the arenas of surgery, trauma, and emergency response medicine. Exsanguination remains the second most prevalent cause of death (27-39%) due to traumatic and polytrauma injury, with 34% of these deaths in the prehospital (e.g. ambulatory) setting. These numbers have persisted despite substantial efforts to develop and deploy synthetic systems that rapidly stem blood loss. The natural hemostatic system (fibrinogen/fibrin), while highly evolutionarily conserved and successful in modest injury situations, critically fails in situations of major hemorrhaging trauma and polytrauma, in part due massive dilution effects, inability to concentrate critical factors, and failure to generate tissue compressive forces during polymerization. In this proposal, our objective is to couple two enabling technologies, i) rationally designed, multivalent fibrin knob peptides, which bind the clotting factor fibrinogen and ii) stimuli-responsive microgels that display triggered assembly into swelling hydrogel assemblies, and to explore the dynamic range of these highly novel fibrinogen (i.e. wound) -triggered microgel assemblies. Our central hypothesis is that stimuli-responsive microgels displaying knob peptides will undergo fibrinogen-initiated assembly into networks that are controlled by the composition of the microgel (ie. peptide density, chain length, crosslinking) and peptide (ie. affinity and multivalency) constituents. To test this hypothesis we will first quantify the binding affinities of engineered synthetic fibrin knob peptides to fibrinogen (Specific Aim 1). Then, following the coupling of said fibrin knob peptides to stimuli-responsive microgels, perform micro-rheological studies to characterize the bio-synthetic hybrid matrix assembly (Specific Aim 2). Coupling our knob peptides, which are capable of "sensing" fibrinogen and fibrin, with stimuli-responsive microgels, which are capable of "responding" via rapid self-assembly into gel matrices, represents a highly innovative approach to hemorrhaging traumatic wounds. The benefit of the technology developed as a consequence of this study is the creation of a hemostatic system that is capable of both concentrating clotting factors and generating compressive forces through triggered swelling, thus serving patients in need of radical hemorrhage control following trauma and polytrauma. The experiments in this proposal will lead to the development of new and powerful wound-responsive biomaterials for hemostasis. The technology developed as a result of this proposal will enable the treatment of trauma victims to prevent their hemorrhagic death, i.e. bleeding to death, one of the primary causes of death due to trauma

Keywords: Abdomen; Address; Affinity; Architecture; base; Behavior; Binding (Molecular Function); Biocompatible Materials; Biological; biosynthetic material; Blood Coagulation Factor; Blood Vessels; Cause of Death; Cessation of life; Characteristics; Chest; Clinical; Colloids; Coupling; crosslink; Cues; Defect; density; design; Development; Electrostatics; Emergency Medicine; Emergency Situation; Engineering; Failure (biologic function); Fibrin; Fibrinogen; Gel; Goals; Hemorrhage; Hemostatic Agents; Hemostatic function; Hybrids; Hydrogels; Injury; innovation; Investigation; Lead; Length; Mechanics; Medicine; Methods; Molecular; N-terminal; novel; Operative Surgical Procedures; particle; Patients; Peptides; polymerization; Polymers; prevent; Property; Proteins; Prunella vulgaris; Research; research study; response; Rheology; Risk; self assembly; stem; Stimulus; Structure; Surface Plasmon Resonance; Swelling; System; Technology; Testing; Time; Tissues; Trauma; Traumatic Hemorrhage; Variant; wound

Relevance: The experiments in this proposal will lead to the development of new and powerful wound-responsive biomaterials for hemostasis. The technology developed as a result of this proposal will enable the treatment of trauma victims to prevent their hemorrhagic death, i.e. bleeding to death, one of the primary causes of death due to trauma

Project start date: 2011-12-15

Project end date: 2013-11-30

Budget start date: 15-DEC-2011

Budget end date: 30-NOV-2012

1R21EB013743-01A1 (2012): $209842


Sponsored Links Excellgen http://Excellgen.com

Recombinant Lentivirus & Adenovirus
High Yield and High Titer up to 1010 (lentivirus) and 1013 (adenovirus) for Guaranteed Expression of GOI. $3000, $2500
Transient Protein Expression in CHO and HEK293 Cells
Transient Expression, Truly Functional Protein, 95% purity, 1~20 mg, fast turnaround. $5500, $3950
Baculovirus Protein Expression
Fast turn around, >95% purity functional protein. No outsourcing to China or India. $5500, $3950